Headline News
HUTCHMED, AstraZeneca Initiate SAMETA Global Phase III Trial of Savolitinib in Combination with PD-L1 Inhibitor IMFINZI® in Patients with MET-Driven Advanced Papillary Renal Cell Carcinoma
by | Nov 1, 2021 | Uncategorized | 0 comments

Recent Comments